ZyVersa Therapeutics

Contributing Author

Recent Articles by ZyVersa Therapeutics

Jul-08	ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds ZVSA GlobeNewswire
Jul-08	ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis ZVSA GlobeNewswire
Jun-26	ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) ZVSA GlobeNewswire
Jun-25	ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator VAR 200 ZVSA GlobeNewswire
May-20	ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases ZVSA GlobeNewswire
May-12	ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress ZVSA GlobeNewswire
May-07	ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update ZVSA GlobeNewswire